Viral Hepatitis C

  • Jiaren Sun
  • Gaurav Chaturvedi
  • Steven A. Weinman
Part of the Molecular Pathology Library book series (MPLB, volume 5)


Chronic hepatitis C is a viral infection characterized by a chronic inflammatory liver disease that frequently leads to cirrhosis and hepatocellular carcinoma. The liver disease is initiated by a host immune response to viral infection of hepatocytes that is ineffective in clearing the virus in at least half of the cases. Once chronic infection is established, the virus modulates host-cell signaling and the metabolic processes that produce lipid accumulation, oxidative stress, insulin resistance, cell-cycle checkpoint disturbances, and fibrogenesis. Some of these effects are secondary to cytokines secreted by infected hepatocytes and immune cells, but others are direct effects of viral proteins on cell processes. This review summarizes the current understanding of the mechanisms by which HCV produces its effects on the liver and the significance of these to disease progression.


Chronic Hepatitis Liver Injury Core Protein Microsomal Triglyceride Transfer Protein Sterol Regulatory Element Binding Protein 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



Work from the author’s laboratories was supported by NIH grants AA012863 (SW) and AI069142 (JS). We gratefully acknowledge Mardelle Susman and Elizabeth Zeller-Last for assistance with manuscript preparation.


  1. 1.
    Alter MJ. Epidemiology of hepatitis C virus infection. World J Gastroenterol. 2007;13(17):2436–41.PubMedGoogle Scholar
  2. 2.
    Muhlberger N, Schwarzer R, Lettmeier B, Sroczynski G, Zeuzem S, Siebert U. HCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity, and mortality. BMC Public Health. 2009;9:34.PubMedGoogle Scholar
  3. 3.
    Lavanchy D. The global burden of hepatitis C. Liver Int. 2009;29 Suppl 1:74–81.PubMedGoogle Scholar
  4. 4.
    Moradpour D, Penin F, Rice CM. Replication of hepatitis C virus. Nat Rev Microbiol. 2007;5(6):453–63.PubMedGoogle Scholar
  5. 5.
    Stamataki Z, Grove J, Balfe P, McKeating JA. Hepatitis C virus entry and neutralization. Clin Liver Dis. 2008;12(3):693–712. x.PubMedGoogle Scholar
  6. 6.
    Bowen DG, Walker CM. Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature. 2005;436(7053):946–52.PubMedGoogle Scholar
  7. 7.
    Tellinghuisen TL, Rice CM. Interaction between hepatitis C virus proteins and host cell factors. Curr Opin Microbiol. 2002;5(4):419–27.PubMedGoogle Scholar
  8. 8.
    Roudot-Thoraval F, Bastie A, Pawlotsky JM, Dhumeaux D. Epidemiological factors affecting the severity of hepatitis C virus-related liver disease: a French survey of 6,664 patients. The Study Group for the Prevalence and the Epidemiology of Hepatitis C Virus. Hepatology. 1997;26(2):485–90.PubMedGoogle Scholar
  9. 9.
    Lindenbach BD, Rice CM. Unravelling hepatitis C virus replication from genome to function. Nature. 2005;436(7053):933–8.PubMedGoogle Scholar
  10. 10.
    Branch AD, Stump DD, Gutierrez JA, Eng F, Walewski JL. The hepatitis C virus alternate reading frame (ARF) and its family of novel products: the alternate reading frame protein/F-protein, the double-frameshift protein, and others. Semin Liver Dis. 2005;25(1):105–17.PubMedGoogle Scholar
  11. 11.
    Goodman ZD, Ishak KG. Histopathology of hepatitis C virus infection. Semin Liver Dis. 1995;15(1):70–81.PubMedGoogle Scholar
  12. 12.
    Seeff LB. Natural history of chronic hepatitis C. Hepatology. 2002;36(5 Suppl 1):S35–46.PubMedGoogle Scholar
  13. 13.
    Poynard T, Ratziu V, Charlotte F, Goodman Z, McHutchison J, Albrecht J. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis c. J Hepatol. 2001;34(5):730–9.PubMedGoogle Scholar
  14. 14.
    Aizawa Y, Shibamoto Y, Takagi I, Zeniya M, Toda G. Analysis of factors affecting the appearance of hepatocellular carcinoma in patients with chronic hepatitis C. A long term follow-up study after histologic diagnosis. Cancer. 2000;89(1):53–9.PubMedGoogle Scholar
  15. 15.
    Yoneyama M. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nature Immunol. 2004;5:730–7.Google Scholar
  16. 16.
    Su AI. Genomic analysis of the host response to hepatitis C virus infection. Proc Natl Acad Sci U S A. 2002;99:15669–74.PubMedGoogle Scholar
  17. 17.
    Thimme R, Bukh J, Spangenberg HC, et al. Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease. Proc Natl Acad Sci U S A. 2002;99(24):15661–8.PubMedGoogle Scholar
  18. 18.
    Thimme R, Oldach D, Chang KM, Steiger C, Ray SC, Chisari FV. Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med. 2001;194(10):1395–406.PubMedGoogle Scholar
  19. 19.
    Golden-Mason L, Castelblanco N, O’Farrelly C, Rosen HR. Phenotypic and functional changes of cytotoxic CD56pos natural T cells determine outcome of acute hepatitis C virus infection. J Virol. 2007;81(17):9292–8.PubMedGoogle Scholar
  20. 20.
    Gale Jr M, Foy EM. Evasion of intracellular host defence by hepatitis C virus. Nature. 2005;436(7053):939–45.PubMedGoogle Scholar
  21. 21.
    Golden-Mason L, Rosen HR. Natural killer cells: primary target for hepatitis C virus immune evasion strategies? Liver Transpl. 2006;12(3):363–72.PubMedGoogle Scholar
  22. 22.
    Boisvert J, Kunkel EJ, Campbell JJ, Keeffe EB, Butcher EC, Greenberg HB. Liver-infiltrating lymphocytes in end-stage hepatitis C virus: subsets, activation status, and chemokine receptor phenotypes. J Hepatol. 2003;38(1):67–75.PubMedGoogle Scholar
  23. 23.
    Gremion C, Grabscheid B, Wolk B, et al. Cytotoxic T lymphocytes derived from patients with chronic hepatitis C virus infection kill bystander cells via Fas-FasL interaction. J Virol. 2004;78(4):2152–7.PubMedGoogle Scholar
  24. 24.
    Wang J, Holmes TH, Cheung R, Greenberg HB, He XS. Expression of chemokine receptors on intrahepatic and peripheral lymphocytes in chronic hepatitis C infection: its relationship to liver inflammation. J Infect Dis. 2004;190(5):989–97.PubMedGoogle Scholar
  25. 25.
    Abrignani S. Antigen-independent activation of resting T-cells in the liver of patients with chronic hepatitis. Dev Biol Stand. 1998;92:191–4.PubMedGoogle Scholar
  26. 26.
    Bigger CB, Brasky KM, Lanford RE. DNA microarray analysis of chimpanzee liver during acute resolving hepatitis C virus infection. J Virol. 2001;75(15):7059–66.PubMedGoogle Scholar
  27. 27.
    Bowen DG, Warren A, Davis T, et al. Cytokine-dependent bystander hepatitis due to intrahepatic murine CD8 T-cell activation by bone marrow-derived cells. Gastroenterology. 2002;123(4):1252–64.PubMedGoogle Scholar
  28. 28.
    Ohta A, Sekimoto M, Sato M, et al. Indispensable role for TNF-alpha and IFN-gamma at the effector phase of liver injury mediated by Th1 cells specific to hepatitis B virus surface antigen. J Immunol. 2000;165(2):956–61.PubMedGoogle Scholar
  29. 29.
    Mochizuki K, Hayashi N, Katayama K, et al. B7/BB-1 expression and hepatitis activity in liver tissues of patients with chronic hepatitis C. Hepatology. 1997;25(3):713–8.PubMedGoogle Scholar
  30. 30.
    Shiraki K, Sugimoto K, Okano H, et al. CD40 expression in HCV-associated chronic liver diseases. Int J Mol Med. 2006;18(4):559–63.PubMedGoogle Scholar
  31. 31.
    Mehal WZ, Juedes AE, Crispe IN. Selective retention of activated CD8+ T cells by the normal liver. J Immunol. 1999;163(6):3202–10.PubMedGoogle Scholar
  32. 32.
    Sun J, Tumurbaatar B, Jia J, et al. Parenchymal expression of CD86/B7.2 contributes to hepatitis C virus-related liver injury. J Virol. 2005;79(16):10730–9.PubMedGoogle Scholar
  33. 33.
    Pillai V, Lee WM, Thiele DL, Karandikar NJ. Clinical responders to antiviral therapy of chronic HCV infection show elevated antiviral CD4+ and CD8+ T-cell responses. J Viral Hepat. 2007;14(5):318–29.PubMedGoogle Scholar
  34. 34.
    Netski DM, Mosbruger T, Astemborski J, Mehta SH, Thomas DL, Cox AL. CD4+ T cell-dependent reduction in hepatitis C virus-specific humoral immune responses after HIV infection. J Infect Dis. 2007;195(6):857–63.PubMedGoogle Scholar
  35. 35.
    Puig M, Mihalik K, Tilton JC, et al. CD4+ immune escape and subsequent T-cell failure following chimpanzee immunization against hepatitis C virus. Hepatology. 2006;44(3):736–45.PubMedGoogle Scholar
  36. 36.
    Grakoui A, Shoukry NH, Woollard DJ, et al. HCV persistence and immune evasion in the absence of memory T cell help. Science. 2003;302(5645):659–62.PubMedGoogle Scholar
  37. 37.
    Smyk-Pearson S, Tester IA, Klarquist J, et al. Spontaneous recovery in acute human hepatitis C virus infection: functional T-cell thresholds and relative importance of CD4 help. J Virol. 2008;82(4):1827–37.PubMedGoogle Scholar
  38. 38.
    Schulze zur Wiesch J, Lauer GM, Day CL, et al. Broad repertoire of the CD4+ Th cell response in spontaneously controlled hepatitis C virus infection includes dominant and highly promiscuous epitopes. J Immunol. 2005;175(6):3603–13.PubMedGoogle Scholar
  39. 39.
    Suvas S, Azkur AK, Kim BS, Kumaraguru U, Rouse BT. CD4(+)CD25(+) regulatory T cells control the severity of viral immunoinflammatory lesions. J Immunol. 2004;172(7):4123–32.PubMedGoogle Scholar
  40. 40.
    Sugimoto K, Ikeda F, Stadanlick J, Nunes FA, Alter HJ, Chang KM. Suppression of HCV-specific T cells without differential hierarchy demonstrated ex vivo in persistent HCV infection. Hepatology. 2003;38(6):1437–48.PubMedGoogle Scholar
  41. 41.
    Heeg MHJ, Ulsenheimer A, Grüner NH, et al. FOXP3 expression in hepatitis C virus-specific CD4+ T cells during acute hepatitis C. Gastroenterology. 2009;137(4):1280-8.Google Scholar
  42. 42.
    Bowen DG, Shoukry NH, Grakoui A, et al. Variable patterns of programmed death-1 expression on fully functional memory T cells after spontaneous resolution of hepatitis C virus infection. J Virol. 2008;82(10):5109–14.PubMedGoogle Scholar
  43. 43.
    Smyk-Pearson S, Golden-Mason L, Klarquist J, et al. Functional suppression by FoxP3+CD4+CD25(high) regulatory T cells during acute hepatitis C virus infection. J Infect Dis. 2008;197(1):46–57.PubMedGoogle Scholar
  44. 44.
    Golden-Mason L, Palmer B, Klarquist J, Mengshol JA, Castelblanco N, Rosen HR. Upregulation of PD-1 expression on circulating and intrahepatic hepatitis C virus-specific CD8+ T cells associated with reversible immune dysfunction. J Virol. 2007;81(17):9249–58.PubMedGoogle Scholar
  45. 45.
    Golden-Mason L, Klarquist J, Wahed AS, Rosen HR. Cutting edge: programmed death-1 expression is increased on immunocytes in chronic hepatitis C virus and predicts failure of response to antiviral therapy: race-dependent differences. J Immunol. 2008;180(6):3637–41.PubMedGoogle Scholar
  46. 46.
    Franceschini D, Paroli M, Francavilla V, et al. PD-L1 negatively regulates CD4+CD25+Foxp3+ Tregs by limiting STAT-5 phosphorylation in patients chronically infected with HCV. J Clin Invest. 2009;119(3):551–64.PubMedGoogle Scholar
  47. 47.
    Mengshol JA, Golden-Mason L, Castelblanco N, et al. Impaired plasmacytoid dendritic cell maturation and differential chemotaxis in chronic hepatitis C virus: associations with antiviral treatment outcomes. Gut. 2009;58(7):964–73.PubMedGoogle Scholar
  48. 48.
    Goutagny N, Vieux C, Decullier E, et al. Quantification and functional analysis of plasmacytoid dendritic cells in patients with chronic hepatitis C virus infection. J Infect Dis. 2004;189(9):1646–55.PubMedGoogle Scholar
  49. 49.
    Liang H, Russell RS, Yonkers NL, et al. Differential effects of hepatitis C virus JFH1 on human myeloid and plasmacytoid dendritic cells. J Virol. 2009;83(11):5693–707.PubMedGoogle Scholar
  50. 50.
    Gondois-Rey F, Dental C, Halfon P, Baumert TF, Olive D, Hirsch I. Hepatitis C virus is a weak inducer of interferon alpha in plasmacytoid dendritic cells in comparison with influenza and human herpesvirus type-1. PLoS One. 2009;4(2):e4319.PubMedGoogle Scholar
  51. 51.
    Shiina M, Rehermann B. Cell culture-produced hepatitis C virus impairs plasmacytoid dendritic cell function. Hepatology. 2008;47(2):385–95.PubMedGoogle Scholar
  52. 52.
    Sarobe P, Lasarte JJ, Casares N, et al. Abnormal priming of CD4(+) T cells by dendritic cells expressing hepatitis C virus core and E1 proteins. J Virol. 2002;76(10):5062–70.PubMedGoogle Scholar
  53. 53.
    Dolganiuc A, Kodys K, Kopasz A, Marshall C, Mandrekar P, Szabo G. Additive inhibition of dendritic cell allostimulatory capacity by alcohol and hepatitis C is not restored by DC maturation and involves abnormal IL-10 and IL-2 induction. Alcohol Clin Exp Res. 2003;27(6):1023–31.PubMedGoogle Scholar
  54. 54.
    Dolganiuc A, Chang S, Kodys K, et al. Hepatitis C virus (HCV) core protein-induced, monocyte-mediated mechanisms of reduced IFN-alpha and plasmacytoid dendritic cell loss in chronic HCV infection. J Immunol. 2006;177(10):6758–68.PubMedGoogle Scholar
  55. 55.
    Saito K, Ait-Goughoulte M, Truscott SM, et al. Hepatitis C virus inhibits cell surface expression of HLA-DR, prevents dendritic cell maturation, and induces interleukin-10 production. J Virol. 2008;82(7):3320–8.PubMedGoogle Scholar
  56. 56.
    Dolganiuc A, Paek E, Kodys K, Thomas J, Szabo G. Myeloid dendritic cells of patients with chronic HCV infection induce proliferation of regulatory T lymphocytes. Gastroenterology. 2008;135(6):2119–27.PubMedGoogle Scholar
  57. 57.
    Decalf J, Fernandes S, Longman R, et al. Plasmacytoid dendritic cells initiate a complex chemokine and cytokine network and are a viable drug target in chronic HCV patients. J Exp Med. 2007;204(10):2423–37.PubMedGoogle Scholar
  58. 58.
    Gehring S, Gregory SH, Wintermeyer P, Aloman C, Wands JR. Generation of immune responses against hepatitis C virus by dendritic cells containing NS5 protein-coated microparticles. Clin Vaccine Immunol. 2009;16(2):163–71.PubMedGoogle Scholar
  59. 59.
    Thomson M, Nascimbeni M, Havert MB, et al. The clearance of hepatitis C virus infection in chimpanzees may not necessarily correlate with the appearance of acquired immunity. J Virol. 2003;77(2):862–70.PubMedGoogle Scholar
  60. 60.
    Deignan T, Curry MP, Doherty DG, et al. Decrease in hepatic CD56(+) T cells and V alpha 24(+) natural killer T cells in chronic hepatitis C viral infection. J Hepatol. 2002;37(1):101–8.PubMedGoogle Scholar
  61. 61.
    Durante-Mangoni E, Wang R, Shaulov A, et al. Hepatic CD1d expression in hepatitis C virus infection and recognition by resident proinflammatory CD1d-reactive T cells. J Immunol. 2004;173(3):2159–66.PubMedGoogle Scholar
  62. 62.
    Ho LP, Urban BC, Thickett DR, Davies RJ, McMichael AJ. Deficiency of a subset of T-cells with immunoregulatory properties in sarcoidosis. Lancet. 2005;365(9464):1062–72.PubMedGoogle Scholar
  63. 63.
    Kinebuchi M, Matsuura A, Ohya K, Abo W, Kitazawa J. Contribution of Va24Vb11 natural killer T cells in Wilsonian hepatitis. Clin Exp Immunol. 2005;139(1):144–51.PubMedGoogle Scholar
  64. 64.
    Liu Z, Govindarajan S, Kaplowitz N. Innate immune system plays a critical role in determining the progression and severity of acetaminophen hepatotoxicity. Gastroenterology. 2004;127(6):1760–74.PubMedGoogle Scholar
  65. 65.
    Forestier C, Molano A, Im JS, et al. Expansion and hyperactivity of CD1d-restricted NKT cells during the progression of systemic lupus erythematosus in (New Zealand Black × New Zealand White)F1 mice. J Immunol. 2005;175(2):763–70.PubMedGoogle Scholar
  66. 66.
    Takeda K, Hayakawa Y, Van Kaer L, Matsuda H, Yagita H, Okumura K. Critical contribution of liver natural killer T cells to a murine model of hepatitis. Proc Natl Acad Sci U S A. 2000;97(10):5498–503.PubMedGoogle Scholar
  67. 67.
    Guebre-Xabier M, Yang S, Lin HZ, Schwenk R, Krzych U, Diehl AM. Altered hepatic lymphocyte subpopulations in obesity-related murine fatty livers: potential mechanism for sensitization to liver damage. Hepatology. 2000;31(3):633–40.PubMedGoogle Scholar
  68. 68.
    Crotta S, Stilla A, Wack A, et al. Inhibition of natural killer cells through engagement of CD81 by the major hepatitis C virus envelope protein. J Exp Med. 2002;195(1):35–41.PubMedGoogle Scholar
  69. 69.
    Herzer K, Falk CS, Encke J, et al. Upregulation of major histocompatibility complex class I on liver cells by hepatitis C virus core protein via p53 and TAP1 impairs natural killer cell cytotoxicity. J Virol. 2003;77(15):8299–309.PubMedGoogle Scholar
  70. 70.
    Khakoo SI, Thio CL, Martin MP, et al. HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science. 2004;305(5685):872–4.PubMedGoogle Scholar
  71. 71.
    Salazar-Mather TP, Hamilton TA, Biron CA. A chemokine-to-cytokine-to-chemokine cascade critical in antiviral defense. J Clin Invest. 2000;105(7):985–93.PubMedGoogle Scholar
  72. 72.
    Liu ZX, Govindarajan S, Okamoto S, Dennert G. NK cells cause liver injury and facilitate the induction of T cell-mediated immunity to a viral liver infection. J Immunol. 2000;164(12):6480–6.PubMedGoogle Scholar
  73. 73.
    Frese M, Schwèarzle V, Barth K, et al. Interferon-gamma inhibits replication of subgenomic and genomic hepatitis C virus RNAs. Hepatology. 2002;35(3):694–703.PubMedGoogle Scholar
  74. 74.
    Betts MR, Price DA, Brenchley JM, et al. The functional profile of primary human antiviral CD8+ T cell effector activity is dictated by cognate peptide concentration. J Immunol. 2004;172(10):6407–17.PubMedGoogle Scholar
  75. 75.
    Gochee PA, Jonsson JR, Clouston AD, Pandeya N, Purdie DM, Powell EE. Steatosis in chronic hepatitis C: association with increased messenger RNA expression of collagen I, tumor necrosis factor-alpha and cytochrome P450 2E1. J Gastroenterol Hepatol. 2003;18(4):386–92.PubMedGoogle Scholar
  76. 76.
    Perlemuter G, Letteron P, Carnot F, et al. Alcohol and hepatitis C virus core protein additively increase lipid peroxidation and synergistically trigger hepatic cytokine expression in a transgenic mouse model. J Hepatol. 2003;39(6):1020–7.PubMedGoogle Scholar
  77. 77.
    Helbig KJ, Ruszkiewicz A, Semendric L, Harley HA, McColl SR, Beard MR. Expression of the CXCR3 ligand I-TAC by hepatocytes in chronic hepatitis C and its correlation with hepatic inflammation. Hepatology. 2004;39(5):1220–9.PubMedGoogle Scholar
  78. 78.
    Shields PL, Morland CM, Salmon M, Qin S, Hubscher SG, Adams DH. Chemokine and chemokine receptor interactions provide a mechanism for selective T cell recruitment to specific liver compartments within hepatitis C-infected liver. J Immunol. 1999;163(11):6236–43.PubMedGoogle Scholar
  79. 79.
    Zeremski M, Petrovic LM, Chiriboga L, et al. Intrahepatic levels of CXCR3-associated chemokines correlate with liver inflammation and fibrosis in chronic hepatitis C. Hepatology. 2008;48(5):1440–50.PubMedGoogle Scholar
  80. 80.
    Butera D, Marukian S, Iwamaye AE, et al. Plasma chemokine levels correlate with the outcome of antiviral therapy in patients with hepatitis C. Blood. 2005;106(4):1175–82.PubMedGoogle Scholar
  81. 81.
    Helbig KJ, Ruszkiewicz A, Lanford RE, et al. Differential expression of the CXCR3 ligands in chronic hepatitis C virus (HCV) infection and their modulation by HCV in vitro. J Virol. 2009;83(2):836–46.PubMedGoogle Scholar
  82. 82.
    Lagging M, Romero AI, Westin J, et al. IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection. Hepatology. 2006;44(6):1617–25.PubMedGoogle Scholar
  83. 83.
    Dhillon AP, Dusheiko GM. Pathology of hepatitis C virus infection. Histopathology. 1995;26(4):297–309.PubMedGoogle Scholar
  84. 84.
    Hu KQ, Currie SL, Shen H, et al. Clinical implications of hepatic steatosis in patients with chronic hepatitis C: a multicenter study of U.S. veterans. Dig Dis Sci. 2007;52(2):570–8.PubMedGoogle Scholar
  85. 85.
    Monto A, Alonzo J, Watson JJ, Grunfeld C, Wright TL. Steatosis in chronic hepatitis C: relative contributions of obesity, diabetes mellitus, and alcohol. Hepatology. 2002;36(3):729–36.PubMedGoogle Scholar
  86. 86.
    Hui JM, Kench J, Farrell GC, et al. Genotype-specific mechanisms for hepatic steatosis in chronic hepatitis C infection. J Gastroenterol Hepatol. 2002;17(8):873–81.PubMedGoogle Scholar
  87. 87.
    Hwang SJ, Luo JC, Chu CW, et al. Hepatic steatosis in chronic hepatitis C virus infection: prevalence and clinical correlation. J Gastroenterol Hepatol. 2001;16(2):190–5.PubMedGoogle Scholar
  88. 88.
    Bach N, Thung SN, Schaffner F. The histological features of chronic hepatitis C and autoimmune chronic hepatitis: a comparative analysis. Hepatology. 1992;15(4):572–7.PubMedGoogle Scholar
  89. 89.
    Lefkowitch JH, Schiff ER, Davis GL, et al. Pathological diagnosis of chronic hepatitis C: a multicenter comparative study with chronic hepatitis B. The Hepatitis Interventional Therapy Group. Gastroenterology. 1993;104(2):595–603.PubMedGoogle Scholar
  90. 90.
    Lonardo A, Adinolfi LE, Loria P, Carulli N, Ruggiero G, Day CP. Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease. Gastroenterology. 2004;126(2):586–97.PubMedGoogle Scholar
  91. 91.
    Castera L, Chouteau P, Hezode C, Zafrani ES, Dhumeaux D, Pawlotsky JM. Hepatitis C virus-induced hepatocellular steatosis. Am J Gastroenterol. 2005;100(3):711–5.PubMedGoogle Scholar
  92. 92.
    Rubbia-Brandt L, Quadri R, Abid K, et al. Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. J Hepatol. 2000;33(1):106–15.PubMedGoogle Scholar
  93. 93.
    Kumar D, Farrell GC, Fung C, George J. Hepatitis C virus genotype 3 is cytopathic to hepatocytes: reversal of hepatic steatosis after sustained therapeutic response. Hepatology. 2002;36(5):1266–72.PubMedGoogle Scholar
  94. 94.
    Rubbia-Brandt L, Leandro G, Spahr L, et al. Liver steatosis in chronic hepatitis C: a morphological sign suggesting infection with HCV genotype 3. Histopathology. 2001;39(2):119–24.PubMedGoogle Scholar
  95. 95.
    Fujie H, Yotsuyanagi H, Moriya K, et al. Steatosis and intrahepatic hepatitis C virus in chronic hepatitis. J Med Virol. 1999;59(2):141–5.PubMedGoogle Scholar
  96. 96.
    Reddy KR, Govindarajan S, Marcellin P, et al. Hepatic steatosis in chronic hepatitis C: baseline host and viral characteristics and influence on response to therapy with peginterferon alpha-2a plus ribavirin. J Viral Hepat. 2008;15(2):129–36.PubMedGoogle Scholar
  97. 97.
    Moucari R, Asselah T, Cazals-Hatem D, et al. Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis. Gastroenterology. 2008;134(2):416–23.PubMedGoogle Scholar
  98. 98.
    Hui JM, Sud A, Farrell GC, et al. Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression [corrected]. Gastroenterology. 2003;125(6):1695–704.PubMedGoogle Scholar
  99. 99.
    Wang CS, Wang ST, Yao WJ, Chang TT, Chou P. Hepatitis C virus infection and the development of type 2 diabetes in a community-based longitudinal study. Am J Epidemiol. 2007;166(2):196–203.PubMedGoogle Scholar
  100. 100.
    Petta S, Camma C, Di Marco V, et al. Insulin resistance and diabetes increase fibrosis in the liver of patients with genotype 1 HCV infection. Am J Gastroenterol. 2008;103(5):1136–44.PubMedGoogle Scholar
  101. 101.
    Fartoux L, Poujol-Robert A, Guechot J, Wendum D, Poupon R, Serfaty L. Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C. Gut. 2005;54(7):1003–8.PubMedGoogle Scholar
  102. 102.
    Serfaty L, Capeau J. Hepatitis C, insulin resistance and diabetes: clinical and pathogenic data. Liver Int. 2009;29 Suppl 2:13–25.PubMedGoogle Scholar
  103. 103.
    Leandro G, Mangia A, Hui J, et al. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology. 2006;130(6):1636–42.PubMedGoogle Scholar
  104. 104.
    Patton HM, Patel K, Behling C, et al. The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. J Hepatol. 2004;40(3):484–90.PubMedGoogle Scholar
  105. 105.
    Fartoux L, Chazouilleres O, Wendum D, Poupon R, Serfaty L. Impact of steatosis on progression of fibrosis in patients with mild hepatitis C. Hepatology. 2005;41(1):82–7.PubMedGoogle Scholar
  106. 106.
    Cross TJ, Quaglia A, Hughes S, Joshi D, Harrison PM. The impact of hepatic steatosis on the natural history of chronic hepatitis C infection. J Viral Hepat. 2009;16(7):492–9.PubMedGoogle Scholar
  107. 107.
    Westin J, Nordlinder H, Lagging M, Norkrans G, Wejstal R. Steatosis accelerates fibrosis development over time in hepatitis C virus genotype 3 infected patients. J Hepatol. 2002;37(6):837–42.PubMedGoogle Scholar
  108. 108.
    Castera L, Hezode C, Roudot-Thoraval F, et al. Worsening of steatosis is an independent factor of fibrosis progression in untreated patients with chronic hepatitis C and paired liver biopsies. Gut. 2003;52(2):288–92.PubMedGoogle Scholar
  109. 109.
    Bugianesi E, Marchesini G, Gentilcore E, et al. Fibrosis in genotype 3 chronic hepatitis C and nonalcoholic fatty liver disease: role of insulin resistance and hepatic steatosis. Hepatology. 2006;44(6):1648–55.PubMedGoogle Scholar
  110. 110.
    Cua IH, Hui JM, Kench JG, George J. Genotype-specific interactions of insulin resistance, steatosis, and fibrosis in chronic hepatitis C. Hepatology. 2008;48(3):723–31.PubMedGoogle Scholar
  111. 111.
    Nieminen U, Arkkila PE, Karkkainen P, Farkkila MA. Effect of steatosis and inflammation on liver fibrosis in chronic hepatitis C. Liver Int. 2009;29(2):153–8.PubMedGoogle Scholar
  112. 112.
    Moriya K, Yotsuyanagi H, Shintani Y, et al. Hepatitis C virus core protein induces hepatic steatosis in transgenic mice. J Gen Virol. 1997;78(Pt 7):1527–31.PubMedGoogle Scholar
  113. 113.
    Chang ML, Yeh CT, Chen JC, et al. Altered expression patterns of lipid metabolism genes in an animal model of HCV core-related, nonobese, modest hepatic steatosis. BMC Genomics. 2008;9:109.PubMedGoogle Scholar
  114. 114.
    Lerat H, Honda M, Beard MR, et al. Steatosis and liver cancer in transgenic mice expressing the structural and nonstructural proteins of hepatitis C virus. Gastroenterology. 2002;122(2):352–65.PubMedGoogle Scholar
  115. 115.
    Barba G, Harper F, Harada T, et al. Hepatitis C virus core protein shows a cytoplasmic localization and associates to cellular lipid storage droplets. Proc Natl Acad Sci U S A. 1997;94(4):1200–5.PubMedGoogle Scholar
  116. 116.
    McLauchlan J. Lipid droplets and hepatitis C virus infection. Biochim Biophys Acta. 2009;1791(6):552–9.PubMedGoogle Scholar
  117. 117.
    Roingeard P, Hourioux C. Hepatitis C virus core protein, lipid droplets and steatosis. J Viral Hepat. 2008;15(3):157–64.PubMedGoogle Scholar
  118. 118.
    Abid K, Pazienza V, de Gottardi A, et al. An in vitro model of hepatitis C virus genotype 3a-associated triglycerides accumulation. J Hepatol. 2005;42(5):744–51.PubMedGoogle Scholar
  119. 119.
    Piodi A, Chouteau P, Lerat H, Hezode C, Pawlotsky JM. Morphological changes in intracellular lipid droplets induced by different hepatitis C virus genotype core sequences and relationship with steatosis. Hepatology. 2008;48(1):16–27.PubMedGoogle Scholar
  120. 120.
    Jhaveri R, McHutchison J, Patel K, Qiang G, Diehl AM. Specific polymorphisms in hepatitis C virus genotype 3 core protein associated with intracellular lipid accumulation. J Infect Dis. 2008;197(2):283–91.PubMedGoogle Scholar
  121. 121.
    Hourioux C, Patient R, Morin A, et al. The genotype 3-specific hepatitis C virus core protein residue phenylalanine 164 increases steatosis in an in vitro cellular model. Gut. 2007;56(9):1302–8.PubMedGoogle Scholar
  122. 122.
    Wang AG, Lee DS, Moon HB, et al. Non-structural 5A protein of hepatitis C virus induces a range of liver pathology in transgenic mice. J Pathol. 2009;219(2):253–62.PubMedGoogle Scholar
  123. 123.
    Sabile A, Perlemuter G, Bono F, et al. Hepatitis C virus core protein binds to apolipoprotein AII and its secretion is modulated by fibrates. Hepatology. 1999;30(4):1064–76.PubMedGoogle Scholar
  124. 124.
    Perlemuter G, Sabile A, Letteron P, et al. Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral-related steatosis. FASEB J. 2002;16(2):185–94.PubMedGoogle Scholar
  125. 125.
    Fukasawa M, Tanaka Y, Sato S, et al. Enhancement of de novo fatty acid biosynthesis in hepatic cell line Huh7 expressing hepatitis C virus core protein. Biol Pharm Bull. 2006;29(9):1958–61.PubMedGoogle Scholar
  126. 126.
    Jackel-Cram C, Babiuk LA, Liu Q. Up-regulation of fatty acid synthase promoter by hepatitis C virus core protein: genotype-3a core has a stronger effect than genotype-1b core. J Hepatol. 2007;46(6):999–1008.PubMedGoogle Scholar
  127. 127.
    Waris G, Felmlee DJ, Negro F, Siddiqui A. Hepatitis C virus induces proteolytic cleavage of sterol regulatory element binding proteins and stimulates their phosphorylation via oxidative stress. J Virol. 2007;81(15):8122–30.PubMedGoogle Scholar
  128. 128.
    Oem JK, Jackel-Cram C, Li YP, et al. Activation of sterol regulatory element-binding protein 1c and fatty acid synthase transcription by hepatitis C virus non-structural protein 2. J Gen Virol. 2008;89(Pt 5):1225–30.PubMedGoogle Scholar
  129. 129.
    Moriishi K, Mochizuki R, Moriya K, et al. Critical role of PA28gamma in hepatitis C virus-associated steatogenesis and hepatocarcinogenesis. Proc Natl Acad Sci U S A. 2007;104(5):1661–6.PubMedGoogle Scholar
  130. 130.
    Kim KH, Hong SP, Kim K, Park MJ, Kim KJ, Cheong J. HCV core protein induces hepatic lipid accumulation by activating SREBP1 and PPARgamma. Biochem Biophys Res Commun. 2007;355(4):883–8.PubMedGoogle Scholar
  131. 131.
    Park CY, Jun HJ, Wakita T, Cheong JH, Hwang SB. Hepatitis C virus nonstructural 4B protein modulates sterol regulatory element-binding protein signaling via the AKT pathway. J Biol Chem. 2009;284(14):9237–46.PubMedGoogle Scholar
  132. 132.
    McPherson S, Jonsson JR, Barrie HD, O’Rourke P, Clouston AD, Powell EE. Investigation of the role of SREBP-1c in the pathogenesis of HCV-related steatosis. J Hepatol. 2008;49(6):1046–54.PubMedGoogle Scholar
  133. 133.
    Tanaka N, Moriya K, Kiyosawa K, Koike K, Gonzalez FJ, Aoyama T. PPARalpha activation is essential for HCV core protein-induced hepatic steatosis and hepatocellular carcinoma in mice. J Clin Invest. 2008;118(2):683–94.PubMedGoogle Scholar
  134. 134.
    Tsutsumi T, Suzuki T, Shimoike T, et al. Interaction of hepatitis C virus core protein with retinoid X receptor alpha modulates its transcriptional activity. Hepatology. 2002;35(4):937–46.PubMedGoogle Scholar
  135. 135.
    Dharancy S, Malapel M, Perlemuter G, et al. Impaired expression of the peroxisome proliferator-activated receptor alpha during hepatitis C virus infection. Gastroenterology. 2005;128(2):334–42.PubMedGoogle Scholar
  136. 136.
    Yamaguchi A, Tazuma S, Nishioka T, et al. Hepatitis C virus core protein modulates fatty acid metabolism and thereby causes lipid accumulation in the liver. Dig Dis Sci. 2005;50(7):1361–71.PubMedGoogle Scholar
  137. 137.
    Kim K, Kim KH, Ha E, Park JY, Sakamoto N, Cheong J. Hepatitis C virus NS5A protein increases hepatic lipid accumulation via induction of activation and expression of PPARgamma. FEBS Lett. 2009;583(17):2720–6.PubMedGoogle Scholar
  138. 138.
    Aytug S, Reich D, Sapiro LE, Bernstein D, Begum N. Impaired IRS-1/PI3-kinase signaling in patients with HCV: a mechanism for increased prevalence of type 2 diabetes. Hepatology. 2003;38(6):1384–92.PubMedGoogle Scholar
  139. 139.
    Kawaguchi T, Ide T, Taniguchi E, et al. Clearance of HCV improves insulin resistance, beta-cell function, and hepatic expression of insulin receptor substrate 1 and 2. Am J Gastroenterol. 2007;102(3):570–6.PubMedGoogle Scholar
  140. 140.
    Kawaguchi T, Yoshida T, Harada M, et al. Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3. Am J Pathol. 2004;165(5):1499–508.PubMedGoogle Scholar
  141. 141.
    Hung CH, Lee CM, Chen CH, et al. Association of inflammatory and anti-inflammatory cytokines with insulin resistance in chronic hepatitis C. Liver Int. 2009;29(7):1086–93.PubMedGoogle Scholar
  142. 142.
    Knobler H, Zhornicky T, Sandler A, Haran N, Ashur Y, Schattner A. Tumor necrosis factor-alpha-induced insulin resistance may mediate the hepatitis C virus-diabetes association. Am J Gastroenterol. 2003;98(12):2751–6.PubMedGoogle Scholar
  143. 143.
    Lecube A, Hernandez C, Genesca J, Simo R. Proinflammatory cytokines, insulin resistance, and insulin secretion in chronic hepatitis C patients: a case-control study. Diabetes Care. 2006;29(5):1096–101.PubMedGoogle Scholar
  144. 144.
    Shintani Y, Fujie H, Miyoshi H, et al. Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology. 2004;126(3):840–8.PubMedGoogle Scholar
  145. 145.
    Hotamisligil GS. The role of TNFalpha and TNF receptors in obesity and insulin resistance. J Intern Med. 1999;245(6):621–5.PubMedGoogle Scholar
  146. 146.
    Miyamoto H, Moriishi K, Moriya K, et al. Involvement of the PA28gamma-dependent pathway in insulin resistance induced by hepatitis C virus core protein. J Virol. 2007;81(4):1727–35.PubMedGoogle Scholar
  147. 147.
    Rui L, Yuan M, Frantz D, Shoelson S, White MF. SOCS-1 and SOCS-3 block insulin signaling by ubiquitin-mediated degradation of IRS1 and IRS2. J Biol Chem. 2002;277(44):42394–8.PubMedGoogle Scholar
  148. 148.
    Ueki K, Kondo T, Tseng YH, Kahn CR. Central role of suppressors of cytokine signaling proteins in hepatic steatosis, insulin resistance, and the metabolic syndrome in the mouse. Proc Natl Acad Sci U S A. 2004;101(28):10422–7.PubMedGoogle Scholar
  149. 149.
    Pazienza V, Clement S, Pugnale P, et al. The hepatitis C virus core protein of genotypes 3a and 1b downregulates insulin receptor substrate 1 through genotype-specific mechanisms. Hepatology. 2007;45(5):1164–71.PubMedGoogle Scholar
  150. 150.
    Wang T, Weinman SA. Causes and consequences of mitochondrial reactive oxygen species generation in hepatitis C. J Gastroenterol Hepatol. 2006;21 Suppl 3:S34–7.PubMedGoogle Scholar
  151. 151.
    Koike K, Miyoshi H. Oxidative stress and hepatitis C viral infection. Hepatol Res. 2006;34(2):65–73.PubMedGoogle Scholar
  152. 152.
    Valgimigli M, Valgimigli L, Trere D, et al. Oxidative stress EPR measurement in human liver by radical-probe technique. Correlation with etiology, histology and cell proliferation. Free Radic Res. 2002;36(9):939–48.PubMedGoogle Scholar
  153. 153.
    Vidali M, Tripodi MF, Ivaldi A, et al. Interplay between oxidative stress and hepatic steatosis in the progression of chronic hepatitis C. J Hepatol. 2008;48(3):399–406.PubMedGoogle Scholar
  154. 154.
    Mitsuyoshi H, Itoh Y, Sumida Y, et al. Evidence of oxidative stress as a cofactor in the development of insulin resistance in patients with chronic hepatitis C. Hepatol Res. 2008;38(4):348–53.PubMedGoogle Scholar
  155. 155.
    Maki A, Kono H, Gupta M, et al. Predictive power of biomarkers of oxidative stress and inflammation in patients with hepatitis C virus-associated hepatocellular carcinoma. Ann Surg Oncol. 2007;14(3):1182–90.PubMedGoogle Scholar
  156. 156.
    Bureau C, Bernad J, Chaouche N, et al. Nonstructural 3 protein of hepatitis C virus triggers an oxidative burst in human monocytes via activation of NADPH oxidase. J Biol Chem. 2001;276(25):23077–83.PubMedGoogle Scholar
  157. 157.
    Nishina S, Hino K, Korenaga M, et al. Hepatitis C virus-induced reactive oxygen species raise hepatic iron level in mice by reducing hepcidin transcription. Gastroenterology. 2008;134(1):226–38.PubMedGoogle Scholar
  158. 158.
    Benali-Furet NL, Chami M, Houel L, et al. Hepatitis C virus core triggers apoptosis in liver cells by inducing ER stress and ER calcium depletion. Oncogene. 2005;24(31):4921–33.PubMedGoogle Scholar
  159. 159.
    Tardif KD, Waris G, Siddiqui A. Hepatitis C virus, ER stress, and oxidative stress. Trends Microbiol. 2005;13(4):159–63.PubMedGoogle Scholar
  160. 160.
    Qadri I, Iwahashi M, Capasso JM, et al. Induced oxidative stress and activated expression of manganese superoxide dismutase during hepatitis C virus replication: role of JNK, p38 MAPK and AP-1. Biochem J. 2004;378(Pt 3):919–28.PubMedGoogle Scholar
  161. 161.
    Piccoli C, Scrima R, Quarato G, et al. Hepatitis C virus protein expression causes calcium-mediated mitochondrial bioenergetic dysfunction and nitro-oxidative stress. Hepatology. 2007;46(1):58–65.PubMedGoogle Scholar
  162. 162.
    Schwer B, Ren S, Pietschmann T, et al. Targeting of hepatitis C virus core protein to mitochondria through a novel C-terminal localization motif. J Virol. 2004;78(15):7958–68.PubMedGoogle Scholar
  163. 163.
    Korenaga M, Wang T, Li Y, et al. Hepatitis C virus core protein inhibits mitochondrial electron transport and increases reactive oxygen species (ROS) production. J Biol Chem. 2005;280(45):37481–8.PubMedGoogle Scholar
  164. 164.
    Li Y, Boehning DF, Qian T, Popov VL, Weinman SA. Hepatitis C virus core protein increases mitochondrial ROS production by stimulation of Ca2+ uniporter activity. FASEB J. 2007;21(10):2474–85.PubMedGoogle Scholar
  165. 165.
    Gong G, Waris G, Tanveer R, Siddiqui A. Human hepatitis C virus NS5A protein alters intracellular calcium levels, induces oxidative stress, and activates STAT-3 and NF-kappa B. Proc Natl Acad Sci U S A. 2001;98(17):9599–604.PubMedGoogle Scholar
  166. 166.
    Dionisio N, Garcia-Mediavilla MV, Sanchez-Campos S, et al. Hepatitis C virus NS5A and core proteins induce oxidative stress-mediated calcium signalling alterations in hepatocytes. J Hepatol. 2009;50(5):872–82.PubMedGoogle Scholar
  167. 167.
    Horner SM, Gale Jr M. Intracellular innate immune cascades and interferon defenses that control hepatitis C virus. J Interferon Cytokine Res. 2009;29(9):489–98.PubMedGoogle Scholar
  168. 168.
    Nomura-Takigawa Y, Nagano-Fujii M, Deng L, et al. Non-structural protein 4A of hepatitis C virus accumulates on mitochondria and renders the cells prone to undergoing mitochondria-mediated apoptosis. J Gen Virol. 2006;87(Pt 7):1935–45.PubMedGoogle Scholar
  169. 169.
    Selimovic D, Hassan M. Inhibition of hepatitis C virus (HCV) core protein-induced cell growth by non-structural protein 4A (NS4A) is mediated by mitochondrial dysregulation. Bosn J Basic Med Sci. 2008;8(1):4–11.PubMedGoogle Scholar
  170. 170.
    Vidali M, Occhino G, Ivaldi A, Rigamonti C, Sartori M, Albano E. Combination of oxidative stress and steatosis is a risk factor for fibrosis in alcohol-drinking patients with chronic hepatitis C. Am J Gastroenterol. 2008;103(1):147–53.PubMedGoogle Scholar
  171. 171.
    Choi J, Ou JH. Mechanisms of liver injury. III. Oxidative stress in the pathogenesis of hepatitis C virus. Am J Physiol Gastrointest Liver Physiol. 2006;290(5):G847–51.PubMedGoogle Scholar
  172. 172.
    Friedman SL. Mechanisms of hepatic fibrogenesis. Gastroenterology. 2008;134(6):1655–69.PubMedGoogle Scholar
  173. 173.
    van der Poorten D, George J. Disease-specific mechanisms of fibrosis: hepatitis C virus and nonalcoholic steatohepatitis. Clin Liver Dis. 2008;12(4):805–24. ix.PubMedGoogle Scholar
  174. 174.
    Kisseleva T, Brenner DA. Role of hepatic stellate cells in fibrogenesis and the reversal of fibrosis. J Gastroenterol Hepatol. 2007;22 Suppl 1:S73–8.PubMedGoogle Scholar
  175. 175.
    Urtasun R, Conde de la Rosa L, Nieto N. Oxidative and nitrosative stress and fibrogenic response. Clin Liver Dis. 2008;12(4):769–90. viii.PubMedGoogle Scholar
  176. 176.
    Taniguchi H, Kato N, Otsuka M, et al. Hepatitis C virus core protein upregulates transforming growth factor-beta 1 transcription. J Med Virol. 2004;72(1):52–9.PubMedGoogle Scholar
  177. 177.
    Nelson DR, Gonzalez-Peralta RP, Qian K, et al. Transforming growth factor-beta 1 in chronic hepatitis C. J Viral Hepat. 1997;4(1):29–35.PubMedGoogle Scholar
  178. 178.
    Gabriel A, Ziolkowski A, Radlowski P, Tomaszek K, Dziambor A. Hepatocyte steatosis in HCV patients promotes fibrosis by enhancing TGF-beta liver expression. Hepatol Res. 2008;38(2):141–6.PubMedGoogle Scholar
  179. 179.
    Schulze-Krebs A, Preimel D, Popov Y, et al. Hepatitis C virus-replicating hepatocytes induce fibrogenic activation of hepatic stellate cells. Gastroenterology. 2005;129(1):246–58.PubMedGoogle Scholar
  180. 180.
    Deng L, Adachi T, Kitayama K, et al. Hepatitis C virus infection induces apoptosis through a Bax-triggered, mitochondrion-mediated, caspase 3-dependent pathway. J Virol. 2008;82(21):10375–85.PubMedGoogle Scholar
  181. 181.
    Zhu H, Dong H, Eksioglu E, et al. Hepatitis C virus triggers apoptosis of a newly developed hepatoma cell line through antiviral defense system. Gastroenterology. 2007;133(5):1649–59.PubMedGoogle Scholar
  182. 182.
    Watanabe A, Hashmi A, Gomes DA, et al. Apoptotic hepatocyte DNA inhibits hepatic stellate cell chemotaxis via toll-like receptor 9. Hepatology. 2007;46(5):1509–18.PubMedGoogle Scholar
  183. 183.
    Bataller R, Paik YH, Lindquist JN, Lemasters JJ, Brenner DA. Hepatitis C virus core and nonstructural proteins induce fibrogenic effects in hepatic stellate cells. Gastroenterology. 2004;126(2):529–40.PubMedGoogle Scholar
  184. 184.
    Shin JY, Hur W, Wang JS, et al. HCV core protein promotes liver fibrogenesis via up-regulation of CTGF with TGF-beta1. Exp Mol Med. 2005;37(2):138–45.PubMedGoogle Scholar
  185. 185.
    Ramirez S, Perez-Del-Pulgar S, Forns X. Virology and pathogenesis of hepatitis C virus recurrence. Liver Transpl. 2008;14 Suppl 2:S27–35.PubMedGoogle Scholar
  186. 186.
    Gatza ML, Chandhasin C, Ducu RI, Marriott SJ. Impact of transforming viruses on cellular mutagenesis, genome stability, and cellular transformation. Environ Mol Mutagen. 2005;45(2–3):304–25.PubMedGoogle Scholar
  187. 187.
    McLaughlin-Drubin ME, Munger K. Viruses associated with human cancer. Biochim Biophys Acta. 2008;1782(3):127–50.PubMedGoogle Scholar
  188. 188.
    Ray RB, Meyer K, Ray R. Hepatitis C virus core protein promotes immortalization of primary human hepatocytes. Virology. 2000;271(1):197–204.PubMedGoogle Scholar
  189. 189.
    Ruggieri A, Murdolo M, Harada T, Miyamura T, Rapicetta M. Cell cycle perturbation in a human hepatoblastoma cell line constitutively expressing Hepatitis C virus core protein. Arch Virol. 2004;149(1):61–74.PubMedGoogle Scholar
  190. 190.
    Tsuchihara K, Hijikata M, Fukuda K, Kuroki T, Yamamoto N, Shimotohno K. Hepatitis C virus core protein regulates cell growth and signal transduction pathway transmitting growth stimuli. Virology. 1999;258(1):100–7.PubMedGoogle Scholar
  191. 191.
    Zemel R, Gerechet S, Greif H, et al. Cell transformation induced by hepatitis C virus NS3 serine protease. J Viral Hepat. 2001;8(2):96–102.PubMedGoogle Scholar
  192. 192.
    Sakamuro D, Furukawa T, Takegami T. Hepatitis C virus nonstructural protein NS3 transforms NIH 3T3 cells. J Virol. 1995;69(6):3893–6.PubMedGoogle Scholar
  193. 193.
    Ghosh AK, Steele R, Meyer K, Ray R, Ray RB. Hepatitis C virus NS5A protein modulates cell cycle regulatory genes and promotes cell growth. J Gen Virol. 1999;80(Pt 5):1179–83.PubMedGoogle Scholar
  194. 194.
    Sun BS, Pan J, Clayton MM, et al. Hepatitis C virus replication in stably transfected HepG2 cells promotes hepatocellular growth and tumorigenesis. J Cell Physiol. 2004;201(3):447–58.PubMedGoogle Scholar
  195. 195.
    Machida K, Cheng KT, Sung VM, et al. Hepatitis C virus induces a mutator phenotype: enhanced mutations of immunoglobulin and protooncogenes. Proc Natl Acad Sci U S A. 2004;101(12):4262–7.PubMedGoogle Scholar
  196. 196.
    Gurtsevitch VE. Human oncogenic viruses: hepatitis B and hepatitis C viruses and their role in hepatocarcinogenesis. Biochemistry (Mosc). 2008;73(5):504–13.Google Scholar
  197. 197.
    Moriya K, Fujie H, Shintani Y, et al. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat Med. 1998;4(9):1065–7.PubMedGoogle Scholar
  198. 198.
    Kim CM, Koike K, Saito I, Miyamura T, Jay G. HBx gene of hepatitis B virus induces liver cancer in transgenic mice. Nature. 1991;351(6324):317–20.PubMedGoogle Scholar
  199. 199.
    Machida K, Tsukamoto H, Mkrtchyan H, et al. Toll-like receptor 4 mediates synergism between alcohol and HCV in hepatic oncogenesis involving stem cell marker Nanog. Proc Natl Acad Sci U S A. 2009;106(5):1548–53.PubMedGoogle Scholar
  200. 200.
    Staib F, Hussain SP, Hofseth LJ, Wang XW, Harris CC. TP53 and liver carcinogenesis. Hum Mutat. 2003;21(3):201–16.PubMedGoogle Scholar
  201. 201.
    Liang TJ, Heller T. Pathogenesis of hepatitis C-associated hepatocellular carcinoma. Gastroenterology. 2004;127(5 Suppl 1):S62–71.PubMedGoogle Scholar
  202. 202.
    Yu J, Zhang L. The transcriptional targets of p53 in apoptosis control. Biochem Biophys Res Commun. 2005;331(3):851–8.PubMedGoogle Scholar
  203. 203.
    Lan KH, Sheu ML, Hwang SJ, et al. HCV NS5A interacts with p53 and inhibits p53-mediated apoptosis. Oncogene. 2002;21(31):4801–11.PubMedGoogle Scholar
  204. 204.
    Majumder M, Ghosh AK, Steele R, Ray R, Ray RB. Hepatitis C virus NS5A physically associates with p53 and regulates p21/waf1 gene expression in a p53-dependent manner. J Virol. 2001;75(3):1401–7.PubMedGoogle Scholar
  205. 205.
    Siavoshian S, Abraham JD, Thumann C, Kieny MP, Schuster C. Hepatitis C virus core, NS3, NS5A, NS5B proteins induce apoptosis in mature dendritic cells. J Med Virol. 2005;75(3):402–11.PubMedGoogle Scholar
  206. 206.
    Chung YL, Sheu ML, Yen SH. Hepatitis C virus NS5A as a potential viral Bcl-2 homologue interacts with Bax and inhibits apoptosis in hepatocellular carcinoma. Int J Cancer. 2003;107(1):65–73.PubMedGoogle Scholar
  207. 207.
    Ray RB, Steele R, Meyer K, Ray R. Transcriptional repression of p53 promoter by hepatitis C virus core protein. J Biol Chem. 1997;272(17):10983–6.PubMedGoogle Scholar
  208. 208.
    Ray RB, Steele R, Meyer K, Ray R. Hepatitis C virus core protein represses p21WAF1/Cip1/Sid1 promoter activity. Gene. 1998;208(2):331–6.PubMedGoogle Scholar
  209. 209.
    Lu W, Lo SY, Chen M, Wu K, Fung YK, Ou JH. Activation of p53 tumor suppressor by hepatitis C virus core protein. Virology. 1999;264(1):134–41.PubMedGoogle Scholar
  210. 210.
    Otsuka M, Kato N, Lan K, et al. Hepatitis C virus core protein enhances p53 function through augmentation of DNA binding affinity and transcriptional ability. J Biol Chem. 2000;275(44):34122–30.PubMedGoogle Scholar
  211. 211.
    Kao CF, Chen SY, Chen JY, Wu Lee YH. Modulation of p53 transcription regulatory activity and post-translational modification by hepatitis C virus core protein. Oncogene. 2004;23(14):2472–83.PubMedGoogle Scholar
  212. 212.
    Banerjee A, Saito K, Meyer K, et al. Hepatitis C virus core protein and cellular protein HAX-1 promote 5-fluorouracil-mediated hepatocyte growth inhibition. J Virol. 2009;83(19):9663–71.PubMedGoogle Scholar
  213. 213.
    Kwun HJ, Jung EY, Ahn JY, Lee MN, Jang KL. p53-dependent transcriptional repression of p21(waf1) by hepatitis C virus NS3. J Gen Virol. 2001;82(Pt 9):2235–41.PubMedGoogle Scholar
  214. 214.
    Wang F, Yoshida I, Takamatsu M, et al. Complex formation between hepatitis C virus core protein and p21Waf1/Cip1/Sdi1. Biochem Biophys Res Commun. 2000;273(2):479–84.PubMedGoogle Scholar
  215. 215.
    Honda M, Kaneko S, Shimazaki T, et al. Hepatitis C virus core protein induces apoptosis and impairs cell-cycle regulation in stably transformed Chinese hamster ovary cells. Hepatology. 2000;31(6):1351–9.PubMedGoogle Scholar
  216. 216.
    Ozturk M. Genetic aspects of hepatocellular carcinogenesis. Semin Liver Dis. 1999;19(3):235–42.PubMedGoogle Scholar
  217. 217.
    Fu XY, Wang HY, Tan L, Liu SQ, Cao HF, Wu MC. Overexpression of p28/gankyrin in human hepatocellular carcinoma and its clinical significance. World J Gastroenterol. 2002;8(4):638–43.PubMedGoogle Scholar
  218. 218.
    Stevaux O, Dyson NJ. A revised picture of the E2F transcriptional network and RB function. Curr Opin Cell Biol. 2002;14(6):684–91.PubMedGoogle Scholar
  219. 219.
    Harbour JW, Dean DC. The Rb/E2F pathway: expanding roles and emerging paradigms. Genes Dev. Oct 1 2000;14(19):2393–2409.Google Scholar
  220. 220.
    Cho J, Baek W, Yang S, Chang J, Sung YC, Suh M. HCV core protein modulates Rb pathway through pRb down-regulation and E2F-1 up-regulation. Biochim Biophys Acta. 2001;1538(1):59–66.PubMedGoogle Scholar
  221. 221.
    Tsukiyama-Kohara K, Tone S, Maruyama I, et al. Activation of the CKI-CDK-Rb-E2F pathway in full genome hepatitis C virus-expressing cells. J Biol Chem. 2004;279(15):14531–41.PubMedGoogle Scholar
  222. 222.
    Munakata T, Nakamura M, Liang Y, Li K, Lemon SM. Down-regulation of the retinoblastoma tumor suppressor by the hepatitis C virus NS5B RNA-dependent RNA polymerase. Proc Natl Acad Sci U S A. 2005;102(50):18159–64.PubMedGoogle Scholar
  223. 223.
    Munakata T, Liang Y, Kim S, et al. Hepatitis C virus induces E6AP-dependent degradation of the retinoblastoma protein. PLoS Pathog. 2007;3(9):1335–47.PubMedGoogle Scholar
  224. 224.
    DeGregori J, Johnson DG. Distinct and overlapping roles for E2F family members in transcription, proliferation and apoptosis. Curr Mol Med. 2006;6(7):739–48.PubMedGoogle Scholar
  225. 225.
    Giacinti C, Giordano A. RB and cell cycle progression. Oncogene. 2006;25(38):5220–7.PubMedGoogle Scholar
  226. 226.
    Paulovich AG, Toczyski DP, Hartwell LH. When checkpoints fail. Cell. 1997;88(3):315–21.PubMedGoogle Scholar
  227. 227.
    Weinberg RA. The retinoblastoma protein and cell cycle control. Cell. 1995;81(3):323–30.PubMedGoogle Scholar
  228. 228.
    Keyomarsi K, Conte Jr D, Toyofuku W, Fox MP. Deregulation of cyclin E in breast cancer. Oncogene. 1995;11(5):941–50.PubMedGoogle Scholar
  229. 229.
    Nielsen NH, Arnerlov C, Cajander S, Landberg G. Cyclin E expression and proliferation in breast cancer. Anal Cell Pathol. 1998;17(3):177–88.PubMedGoogle Scholar
  230. 230.
    Bortner DM, Rosenberg MP. Induction of mammary gland hyperplasia and carcinomas in transgenic mice expressing human cyclin E. Mol Cell Biol. 1997;17(1):453–9.PubMedGoogle Scholar
  231. 231.
    Cho JW, Baek WK, Suh SI, et al. Hepatitis C virus core protein promotes cell proliferation through the upregulation of cyclin E expression levels. Liver. 2001;21(2):137–42.PubMedGoogle Scholar
  232. 232.
    Matsuda Y, Ichida T, Genda T, Yamagiwa S, Aoyagi Y, Asakura H. Loss of p16 contributes to p27 sequestration by cyclin D(1)-cyclin-dependent kinase 4 complexes and poor prognosis in hepatocellular carcinoma. Clin Cancer Res. 2003;9(9):3389–96.PubMedGoogle Scholar
  233. 233.
    Han J, Tsukada Y, Hara E, Kitamura N, Tanaka T. Hepatocyte growth factor induces redistribution of p21(CIP1) and p27(KIP1) through ERK-dependent p16(INK4a) up-regulation, leading to cell cycle arrest at G1 in HepG2 hepatoma cells. J Biol Chem. 2005;280(36):31548–56.PubMedGoogle Scholar
  234. 234.
    Wu TH, Yang RL, Xie LP, et al. Inhibition of cell growth and induction of G1-phase cell cycle arrest in hepatoma cells by steroid extract from Meretrix meretrix. Cancer Lett. 2006;232(2):199–205.PubMedGoogle Scholar
  235. 235.
    Matsuda Y, Ichida T. p16 and p27 are functionally correlated during the progress of hepatocarcinogenesis. Med Mol Morphol. 2006;39(4):169–75.PubMedGoogle Scholar
  236. 236.
    Li X, Hui AM, Sun L, et al. p16INK4A hypermethylation is associated with hepatitis virus infection, age, and gender in hepatocellular carcinoma. Clin Cancer Res. 2004;10(22):7484–9.PubMedGoogle Scholar
  237. 237.
    Salmena L, Carracedo A, Pandolfi PP. Tenets of PTEN tumor suppression. Cell. 2008;133(3):403–14.PubMedGoogle Scholar
  238. 238.
    Yao YJ, Ping XL, Zhang H, et al. PTEN/MMAC1 mutations in hepatocellular carcinomas. Oncogene. 1999;18(20):3181–5.PubMedGoogle Scholar
  239. 239.
    Wu SK, Wang BJ, Yang Y, Feng XH, Zhao XP, Yang DL. Expression of PTEN, PPM1A and P-Smad2 in hepatocellular carcinomas and adjacent liver tissues. World J Gastroenterol. 2007;13(34):4554–9.PubMedGoogle Scholar
  240. 240.
    Dong-Dong L, Xi-Ran Z, Xiang-Rong C. Expression and significance of new tumor suppressor gene PTEN in primary liver cancer. J Cell Mol Med. 2003;7(1):67–71.PubMedGoogle Scholar
  241. 241.
    Podsypanina K, Ellenson LH, Nemes A, et al. Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc Natl Acad Sci U S A. 1999;96(4):1563–8.PubMedGoogle Scholar
  242. 242.
    Stiles B, Wang Y, Stahl A, et al. Liver-specific deletion of negative regulator Pten results in fatty liver and insulin hypersensitivity [corrected]. Proc Natl Acad Sci U S A. 2004;101(7):2082–7.PubMedGoogle Scholar
  243. 243.
    Horie Y, Suzuki A, Kataoka E, et al. Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas. J Clin Invest. 2004;113(12):1774–83.PubMedGoogle Scholar
  244. 244.
    Tate G, Suzuki T, Mitsuya T. Mutation of the PTEN gene in a human hepatic angiosarcoma. Cancer Genet Cytogenet. 2007;178(2):160–2.PubMedGoogle Scholar
  245. 245.
    Wang H, Quah SY, Dong JM, Manser E, Tang JP, Zeng Q. PRL-3 down-regulates PTEN expression and signals through PI3K to promote epithelial-mesenchymal transition. Cancer Res. 2007;67(7):2922–6.PubMedGoogle Scholar
  246. 246.
    Rahman MA, Kyriazanos ID, Ono T, et al. Impact of PTEN expression on the outcome of hepatitis C virus-positive cirrhotic hepatocellular carcinoma patients: possible relationship with COX II and inducible nitric oxide synthase. Int J Cancer. 2002;100(2):152–7.PubMedGoogle Scholar
  247. 247.
    Tsutsumi T, Suzuki T, Moriya K, et al. Hepatitis C virus core protein activates ERK and p38 MAPK in cooperation with ethanol in transgenic mice. Hepatology. 2003;38(4):820–8.PubMedGoogle Scholar
  248. 248.
    Macdonald A, Crowder K, Street A, McCormick C, Saksela K, Harris M. The hepatitis C virus non-structural NS5A protein inhibits activating protein-1 function by perturbing ras-ERK pathway signaling. J Biol Chem. 2003;278(20):17775–84.PubMedGoogle Scholar
  249. 249.
    Hassan M, Ghozlan H, Abdel-Kader O. Activation of c-Jun NH2-terminal kinase (JNK) signaling pathway is essential for the stimulation of hepatitis C virus (HCV) non-structural protein 3 (NS3)-mediated cell growth. Virology. 2005;333(2):324–36.PubMedGoogle Scholar
  250. 250.
    Zhao LJ, Wang L, Ren H, et al. Hepatitis C virus E2 protein promotes human hepatoma cell proliferation through the MAPK/ERK signaling pathway via cellular receptors. Exp Cell Res. 2005;305(1):23–32.PubMedGoogle Scholar
  251. 251.
    Sato Y, Kato J, Takimoto R, et al. Hepatitis C virus core protein promotes proliferation of human hepatoma cells through enhancement of transforming growth factor alpha expression via activation of nuclear factor-kappaB. Gut. 2006;55(12):1801–8.PubMedGoogle Scholar
  252. 252.
    Schmitz KJ, Wohlschlaeger J, Lang H, et al. Activation of the ERK and AKT signalling pathway predicts poor prognosis in hepatocellular carcinoma and ERK activation in cancer tissue is associated with hepatitis C virus infection. J Hepatol. 2008;48(1):83–90.PubMedGoogle Scholar
  253. 253.
    Koike K, Tsutsumi T, Miyoshi H, et al. Molecular basis for the synergy between alcohol and hepatitis C virus in hepatocarcinogenesis. J Gastroenterol Hepatol. 2008;23 Suppl 1:S87–91.PubMedGoogle Scholar
  254. 254.
    Polakis P. Wnt signaling and cancer. Genes Dev. 2000;14(15):1837–51.PubMedGoogle Scholar
  255. 255.
    Fujie H, Moriya K, Shintani Y, et al. Frequent beta-catenin aberration in human hepatocellular carcinoma. Hepatol Res. 2001;20(1):39–51.PubMedGoogle Scholar
  256. 256.
    Edamoto Y, Hara A, Biernat W, et al. Alterations of RB1, p53 and Wnt pathways in hepatocellular carcinomas associated with hepatitis C, hepatitis B and alcoholic liver cirrhosis. Int J Cancer. 2003;106(3):334–41.PubMedGoogle Scholar
  257. 257.
    Street A, Macdonald A, McCormick C, Harris M. Hepatitis C virus NS5A-mediated activation of phosphoinositide 3-kinase results in stabilization of cellular beta-catenin and stimulation of beta-catenin-responsive transcription. J Virol. 2005;79(8):5006–16.PubMedGoogle Scholar
  258. 258.
    Boyault S, Rickman DS, de Reynies A, et al. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology. 2007;45(1):42–52.PubMedGoogle Scholar
  259. 259.
    Calvisi DF, Ladu S, Conner EA, Factor VM, Thorgeirsson SS. Disregulation of E-cadherin in transgenic mouse models of liver cancer. Lab Invest. 2004;84(9):1137–47.PubMedGoogle Scholar
  260. 260.
    Kwon GY, Yoo BC, Koh KC, Cho JW, Park WS, Park CK. Promoter methylation of E-cadherin in hepatocellular carcinomas and dysplastic nodules. J Korean Med Sci. 2005;20(2):242–7.PubMedGoogle Scholar
  261. 261.
    Iso Y, Sawada T, Okada T, Kubota K. Loss of E-cadherin mRNA and gain of osteopontin mRNA are useful markers for detecting early recurrence of HCV-related hepatocellular carcinoma. J Surg Oncol. 2005;92(4):304–11.PubMedGoogle Scholar
  262. 262.
    Lee HH, Uen YH, Tian YF, et al. Wnt-1 protein as a prognostic biomarker for hepatitis B-related and hepatitis C-related hepatocellular carcinoma after surgery. Cancer Epidemiol Biomarkers Prev. 2009;18(5):1562–9.PubMedGoogle Scholar
  263. 263.
    Yang B, Guo M, Herman JG, Clark DP. Aberrant promoter methylation profiles of tumor suppressor genes in hepatocellular carcinoma. Am J Pathol. 2003;163(3):1101–7.PubMedGoogle Scholar
  264. 264.
    Matsuzaki K, Murata M, Yoshida K, et al. Chronic inflammation associated with hepatitis C virus infection perturbs hepatic transforming growth factor beta signaling, promoting cirrhosis and hepatocellular carcinoma. Hepatology. 2007;46(1):48–57.PubMedGoogle Scholar
  265. 265.
    Giannelli G, Bergamini C, Fransvea E, Sgarra C, Antonaci S. Laminin-5 with transforming growth factor-beta1 induces epithelial to mesenchymal transition in hepatocellular carcinoma. Gastroenterology. 2005;129(5):1375–83.PubMedGoogle Scholar
  266. 266.
    Battaglia S, Benzoubir N, Nobilet S, et al. Liver cancer-derived hepatitis C virus core proteins shift TGF-beta responses from tumor suppression to epithelial-mesenchymal transition. PLoS One. 2009;4(2):e4355.PubMedGoogle Scholar
  267. 267.
    Lilley CE, Schwartz RA, Weitzman MD. Using or abusing: viruses and the cellular DNA damage response. Trends Microbiol. 2007;15(3):119–26.PubMedGoogle Scholar
  268. 268.
    Ariumi Y, Kuroki M, Dansako H, et al. The DNA damage sensors ataxia-telangiectasia mutated kinase and checkpoint kinase 2 are required for hepatitis C virus RNA replication. J Virol. 2008;82(19):9639–46.PubMedGoogle Scholar
  269. 269.
    Machida K, Cheng KT, Sung VM, Lee KJ, Levine AM, Lai MM. Hepatitis C virus infection activates the immunologic (type II) isoform of nitric oxide synthase and thereby enhances DNA ­damage and mutations of cellular genes. J Virol. 2004;78(16):8835–43.PubMedGoogle Scholar
  270. 270.
    Myong S, Bruno MM, Pyle AM, Ha T. Spring-loaded mechanism of DNA unwinding by hepatitis C virus NS3 helicase. Science. 2007;317(5837):513–6.PubMedGoogle Scholar
  271. 271.
    Pang PS, Jankowsky E, Planet PJ, Pyle AM. The hepatitis C viral NS3 protein is a processive DNA helicase with cofactor enhanced RNA unwinding. EMBO J. 2002;21(5):1168–76.PubMedGoogle Scholar
  272. 272.
    Lai CK, Jeng KS, Machida K, Cheng YS, Lai MM. Hepatitis C virus NS3/4A protein interacts with ATM, impairs DNA repair and enhances sensitivity to ionizing radiation. Virology. 2008;370(2):295–309.PubMedGoogle Scholar
  273. 273.
    Ray RB, Lagging LM, Meyer K, Ray R. Hepatitis C virus core ­protein cooperates with ras and transforms primary rat embryo fibroblasts to tumorigenic phenotype. J Virol. 1996;70(7):4438–43.PubMedGoogle Scholar
  274. 274.
    Yoshida T, Hanada T, Tokuhisa T, et al. Activation of STAT3 by the hepatitis C virus core protein leads to cellular transformation. J Exp Med. 2002;196(5):641–53.PubMedGoogle Scholar
  275. 275.
    Marusawa H, Hijikata M, Chiba T, Shimotohno K. Hepatitis C virus core protein inhibits Fas- and tumor necrosis factor alpha-mediated apoptosis via NF-kappaB activation. J Virol. 1999;73(6):4713–20.PubMedGoogle Scholar
  276. 276.
    Zhu N, Khoshnan A, Schneider R, et al. Hepatitis C virus core protein binds to the cytoplasmic domain of tumor necrosis factor (TNF) receptor 1 and enhances TNF-induced apoptosis. J Virol. 1998;72(5):3691–7.PubMedGoogle Scholar
  277. 277.
    Machida K, Tsukiyama-Kohara K, Seike E, et al. Inhibition of cytochrome c release in Fas-mediated signaling pathway in transgenic mice induced to express hepatitis C viral proteins. J Biol Chem. 2001;276(15):12140–6.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Jiaren Sun
  • Gaurav Chaturvedi
  • Steven A. Weinman
    • 1
  1. 1.Department of Internal MedicineUniversity of Kansas Medical CenterKansas CityUSA

Personalised recommendations